Sulforaphane prevents the development of cardiomyopathy in type 2 diabetic mice probably by reversing oxidative stress-induced inhibition of LKB1/AMPK pathway

Journal of Molecular and Cellular Cardiology

Volumn 77, Issue , 2014, Pages 42-52

  Zhang, Zhiguo ^a,b   Wang, Shudong ^a,b   Zhou, Shanshan ^a,b   Yan, Xiaoqing ^b,c   Wang, Yonggang ^a,b   Chen, Jing ^b   Mellen, Nicholas ^b   Kong, Maiying ^d   Gu, Junlian ^b,e   Tan, Yi ^b,c   Zheng, Yang ^a   Cai, Lu ^b,c  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b University of Louisville School of Medicine   (United States)

^c WENZHOU MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF LOUISVILLE   (United States)

^e SHANDONG UNIVERSITY   (China)

Author keywords

Cardiac lipotoxicity; Cardiomyopathy; LKB1 AMPK pathway; Oxidative stress; Sulforaphane; Type 2 diabetes

Indexed keywords

3 NITROTYROSINE; 4 HYDROXYNONENAL; ACETYL COENZYME A CARBOXYLASE; CARNITINE PALMITOYLTRANSFERASE I; CONNECTIVE TISSUE GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE; PROTEIN KINASE LKB1; PROTEIN ULK1; SIRTUIN 1; STREPTOZOCIN; SULFORAPHANE; TRANSCRIPTION FACTOR NRF2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ADENYLATE KINASE; CARDIOTONIC AGENT; ISOTHIOCYANIC ACID DERIVATIVE; PROTEIN SERINE THREONINE KINASE; STK11 PROTEIN, MOUSE; SULFORAFAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; C57BL 6 MOUSE; CARDITIS; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DOWN REGULATION; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE; HEART FUNCTION; HEART MUSCLE FIBROSIS; HISTOLOGY; HO 1 GENE; HYPERGLYCEMIA; IMMUNOPRECIPITATION; INSULIN RESISTANCE; LIPID DIET; LIPID STORAGE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NQO1 GENE; OXIDATIVE STRESS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TRANSTHORACIC ECHOCARDIOGRAPHY; UPREGULATION; WESTERN BLOTTING; ADVERSE EFFECTS; ANIMAL; AUTOPHAGY; C57BL MOUSE; COMPLICATION; DIABETIC CARDIOMYOPATHIES; EXPERIMENTAL DIABETES MELLITUS; HEART MUSCLE; LIPID METABOLISM; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

MUS;

ADENYLATE KINASE; ANIMALS; AUTOPHAGY; CARDIOTONIC AGENTS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; DIET, HIGH-FAT; ISOTHIOCYANATES; LIPID METABOLISM; MALE; MICE, INBRED C57BL; MYOCARDIUM; OXIDATIVE STRESS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION;

EID: 84908376463     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2014.09.022     Document Type: Article

References (59)

1. Danaei G., Finucane M.M., Lu Y., Singh G.M., Cowan M.J., Paciorek C.J., et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370country-years and 2.7 million participants. Lancet 2011, 378:31-40.
2. Association A.D. Diagnosis and classification of diabetes mellitus. Diabetes Care 2014, 37:S81-S90.
3. Lteif A.A., Mather K.J., Clark C.M. Diabetes and heart disease an evidence-driven guide to risk factors management in diabetes. Cardiol Rev 2003, 11:262-274.
4. Wilson P.W. Diabetes mellitus and coronary heart disease. Endocrinol Metab Clin North Am 2001, 30:857-881.
5. Rubler S., Dlugash J., Yuceoglu Y.Z., Kumral T., Branwood A.W., Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972, 30:595-602.
6. Palomer X., Salvado L., Barroso E., Vazquez-Carrera M. An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy. Int J Cardiol 2013, 168:3160-3172.
7. Ussher J.R. The role of cardiac lipotoxicity in the pathogenesis of diabetic cardiomyopathy. Expert Rev Cardiovasc Ther 2014, 12:345-358.
8. Fang Z.Y., Prins J.B., Marwick T.H. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 2004, 25:543-567.
9. Hardie D.G., Scott J.W., Pan D.A., Hudson E.R. Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett 2003, 546:113-120.
10. Woods A., Johnstone S.R., Dickerson K., Leiper F.C., Fryer L.G.D., Neumann D., et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 2003, 13:2004-2008.
11. Dunlop E.A., Tee A.R. The kinase triad, AMPK, mTORC1 and ULK1, maintains energy and nutrient homoeostasis. Biochem Soc Trans 2013, 41:939-943.
12. Singh R., Kaushik S., Wang Y., Xiang Y., Novak I., Komatsu M., et al. Autophagy regulates lipid metabolism. Nature 2009, 458:1131-1135.
13. 1H-magnetic resonance spectroscopy study. Circulation 2007, 116:1170-1175.
14. Rijzewijk L.J., van der Meer R.W., Smit J.W., Diamant M., Bax J.J., Hammer S., et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol 2008, 52:1793-1799.
15. Lewin T.M., Coleman R.A. Regulation of myocardial triacylglycerol synthesis and metabolism. Biochim Biophys Acta 2003, 1634:63-75.
16. Gray S., Kim J.K. New insights into insulin resistance in the diabetic heart. Trends Endocrinol Metab 2011, 22:394-403.
17. Hardie D.G. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 2007, 8:774-785.
18. Reznick R.M., Shulman G.I. The role of AMP-activated protein kinase in mitochondrial biogenesis. J Physiol 2006, 574:33-39.
19. Bai Y., Cui W., Xin Y., Miao X., Barati M.T., Zhang C., et al. Prevention by sulforaphane of diabetic cardiomyopathy is associated with up-regulation of Nrf2 expression and transcription activation. J Mol Cell Cardiol 2013, 57:82-95.
20. Wang Y., Zhang Z., Sun W., Tan Y., Liu Y., Zheng Y., et al. Sulforaphane attenuation of type 2 diabetes-induced aortic damage was associated with the upregulation of Nrf2 expression and function. Oxid Med Cell Longev 2014, 2014:123963.
21. Wang Y., Zhang Z., Guo W., Sun W., Miao X., Wu H., et al. Sulforaphane reduction of testicular apoptotic cell death in diabetic mice is associated with the upregulation of Nrf2 expression and function. Am J Physiol Endocrinol Metab 2014, 307:E14-E23.
22. Choi K.M., Lee Y.S., Kim W., Kim S.J., Shin K.O., Yu J.Y., et al. Sulforaphane attenuates obesity by inhibiting adipogenesis and activating the AMPK pathway in obese mice. J Nutr Biochem 2014, 25:201-207.
23. Taylor S.I. Deconstructing type 2 diabetes. Cell 1999, 97:9-12.
24. 1H-spectroscopic study in Zucker diabetic fatty rats. Diabetes 2003, 52:138-144.
25. Chen H., Charlat O., Tartaglia L.A., Woolf E.A., Weng X., Ellis S.J., et al. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996, 84:491-495.
26. Moran T.H., Bi S. Hyperphagia and obesity in OLETF rats lacking CCK-1 receptors. Philos Trans R Soc Lond B Biol Sci 2006, 361:1211-1218.
27. Zhao Y., Tan Y., Xi S., Li Y., Li C., Cui J., et al. A novel mechanism by which SDF-1beta protects cardiac cells from palmitate-induced endoplasmic reticulum stress and apoptosis via CXCR7 and AMPK/p38 MAPK-mediated interleukin-6 generation. Diabetes 2013, 62:2545-2558.
28. Srinivasan K., Ramarao P. Animal models in type 2 diabetes research: an overview. Indian J Med Res 2007, 125:451-472.
29. Danda R.S., Habiba N.M., Rincon-Choles H., Bhandari B.K., Barnes J.L., Abboud H.E., et al. Kidney involvement in a nongenetic rat model of type 2 diabetes. Kidney Int 2005, 68:2562-2571.
30. Feng M., Whitesall S., Zhang Y., Beibel M., D'Alecy L., DiPetrillo K. Validation of volume-pressure recording tail-cuff blood pressure measurements. Am J Hypertens 2008, 21:1288-1291.
31. Sun W., Zhang Z., Chen Q., Yin X., Fu Y., Zheng Y., et al. Magnolia extract (BL153) protection of heart from lipid accumulation caused cardiac oxidative damage, inflammation, and cell death in high-fat diet fed mice. Oxid Med Cell Longev 2014, 2014:205849.
32. Zhou G., Li X., Hein D.W., Xiang X., Marshall J.P., Prabhu S.D., et al. Metallothionein suppresses angiotensin II-induced nicotinamide adenine dinucleotide phosphate oxidase activation, nitrosative stress, apoptosis, and pathological remodeling in the diabetic heart. J Am Coll Cardiol 2008, 52:655-666.
33. Tan Y., Ichikawa T., Li J., Si Q., Yang H., Chen X., et al. Diabetic downregulation of Nrf2 activity via ERK contributes to oxidative stress-induced insulin resistance in cardiac cells in vitro and in vivo. Diabetes 2011, 60:625-633.
34. Wang Y., Feng W., Xue W., Tan Y., Hein D.W., Li X.K., et al. Inactivation of GSK-3beta by metallothionein prevents diabetes-related changes in cardiac energy metabolism, inflammation, nitrosative damage, and remodeling. Diabetes 2009, 58:1391-1402.
35. Ueno M., Suzuki J., Zenimaru Y., Takahashi S., Koizumi T., Noriki S., et al. Cardiac overexpression of hormone-sensitive lipase inhibits myocardial steatosis and fibrosis in streptozotocin diabetic mice. Am J Physiol Endocrinol Metab 2008, 294:E1109-E1118.
36. Dolinsky V.W., Chan A.Y., Robillard Frayne I., Light P.E., Des Rosiers C., Dyck J.R. Resveratrol prevents the prohypertrophic effects of oxidative stress on LKB1. Circulation 2009, 119:1643-1652.
37. Inoue T., Kobayashi K., Inoguchi T., Sonoda N., Maeda Y., Hirata E., et al. Downregulation of adipose triglyceride lipase in the heart aggravates diabetic cardiomyopathy in db/db mice. Biochem Biophys Res Commun 2013, 438:224-229.
38. Guleria R.S., Singh A.B., Nizamutdinova I.T., Souslova T., Mohammad A.A., Kendall J.A., et al. Activation of retinoid receptor-mediated signaling ameliorates diabetes-induced cardiac dysfunction in Zucker diabetic rats. J Mol Cell Cardiol 2013, 57:106-118.
39. Belke D.D., Larsen T.S., Gibbs E.M., Severson D.L. Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am J Physiol Endocrinol Metab 2000, 279:E1104-E1113.
40. Mansor L.S., Gonzalez E.R., Cole M.A., Tyler D.J., Beeson J.H., Clarke K., et al. Cardiac metabolism in a new rat model of type 2 diabetes using high-fat diet with low dose streptozotocin. Cardiovasc Diabetol 2013, 12:136.
41. Labbe S.M., Grenier-Larouche T., Noll C., Phoenix S., Guerin B., Turcotte E.E., et al. Increased myocardial uptake of dietary fatty acids linked to cardiac dysfunction in glucose-intolerant humans. Diabetes 2012, 61:2701-2710.
42. Rijzewijk L.J., van der Meer R.W., Lamb H.J., de Jong H.W., Lubberink M., Romijn J.A., et al. Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol 2009, 54:1524-1532.
43. Nakanishi T., Kato S. Impact of diabetes mellitus on myocardial lipid deposition: an autopsy study. Pathol Res Pract 2014, 10.1016/j.prp.2014.04.008.
44. Aguilar D., Chan W., Bozkurt B., Ramasubbu K., Deswal A. Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail 2011, 4:53-58.
45. Turdi S., Fan X., Li J., Zhao J., Huff A.F., Du M., et al. AMP-activated protein kinase deficiency exacerbates aging-induced myocardial contractile dysfunction. Aging Cell 2010, 9:592-606.
46. Nagendran J., Waller T.J., Dyck J.R. AMPK signalling and the control of substrate use in the heart. Mol Cell Endocrinol 2013, 366:180-193.
47. Xie Z., Lau K., Eby B., Lozano P., He C., Pennington B., et al. Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice. Diabetes 2011, 60:1770-1778.
48. Shibata M., Yoshimura K., Furuya N., Koike M., Ueno T., Komatsu M., et al. The MAP1-LC3 conjugation system is involved in lipid droplet formation. Biochem Biophys Res Commun 2009, 382:419-423.
49. Kandadi M.R., Hu N., Ren J. ULK1 plays a critical role in AMPK-mediated myocardial autophagy and contractile dysfunction following acute alcohol challenge. Curr Pharm Des 2013, 19:4874-4887.
50. Lopaschuk G.D. Malonyl CoA control of fatty acid oxidation in the diabetic rat heart. Adv Exp Med Biol 2001, 498:155-165.
51. Kudo N., Gillespie J.G., Kung L., Witters L.A., Schulz R., Clanachan A.S., et al. Characterization of 5'AMP-activated protein kinase activity in the heart and its role in inhibiting acetyl-CoA carboxylase during reperfusion following ischemia. Biochim Biophys Acta 1996, 1301:67-75.
52. Folmes C.D., Lopaschuk G.D. Role of malonyl-CoA in heart disease and the hypothalamic control of obesity. Cardiovasc Res 2007, 73:278-287.
53. He L., Kim T., Long Q., Liu J., Wang P., Zhou Y., et al. Carnitine palmitoyltransferase-1b deficiency aggravates pressure overload-induced cardiac hypertrophy caused by lipotoxicity. Circulation 2012, 126:1705-1716.
54. Duncan J.G., Finck B.N. The PPARalpha-PGC-1alpha axis controls cardiac energy metabolism in healthy and diseased myocardium. PPAR Res 2008, 2008:253817.
55. Nisoli E., Carruba M.O. Nitric oxide and mitochondrial biogenesis. J Cell Sci 2006, 119:2855-2862.
56. Brandauer J., Vienberg S.G., Andersen M.A., Ringholm S., Risis S., Larsen P.S., et al. AMP-activated protein kinase regulates nicotinamide phosphoribosyl transferase expression in skeletal muscle. J Physiol 2013, 591:5207-5220.
57. Uchida K. 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog Lipid Res 2003, 42:318-343.
58. Wagner T.M., Mullally J.E., Fitzpatrick F.A. Reactive lipid species from cyclooxygenase-2 inactivate tumor suppressor LKB1/STK11: cyclopentenone prostaglandins and 4-hydroxy-2-nonenal covalently modify and inhibit the AMP-kinase kinase that modulates cellular energy homeostasis and protein translation. J Biol Chem 2006, 281:2598-2604.
59. Ishii T., Itoh K., Yamamoto M. Roles of Nrf2 in activation of antioxidant enzyme genes via antioxidant responsive elements. Methods Enzymol 2002, 348:182-190.